drugset
Drugs / LBL-024
last change Sep 2026 re-read 9 days ago

LBL-024

Developed for
neuroendocrine carcinoma · colorectal carcinoma · high grade malignant neoplasm · melanoma · neoplasm · ovarian cancer · triple-negative breast carcinoma
Investigated by
Nanjing Leads Biolabs Co.,Ltd · Peking University Cancer Hospital & Institute · Sun Yat-sen University Cancer Center · Shanghai Zhongshan Hospital · The First Affiliated Hospital with Nanjing Medical University

Trials 10

today NCT07791758 · Ph 1/2 NCT07720193 · Ph 3 NCT07331155 · Ph 2 NCT07281976 · Ph 1/2 NCT07042802 · Ph 1/2 NCT07111546 · Ph 2 NCT07099430 · Ph 1/2 NCT06783647 · Ph 2 NCT06157827 · Ph 1/2 NCT05170958 · Ph 1/2
2022202320242025202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/26 trials
Phase 1/2 NCT07791758 Sep 2026 → Sep 2030 expected colorectal carcinoma Nanjing Leads Biolabs Co.,Ltd Not yet recruiting No outcome recorded
Phase 1/2 NCT07281976 Jan 2026 → Dec 2027 expected triple-negative breast carcinoma Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07042802 Dec 2025 → Dec 2027 expected ovarian cancer Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07099430 Sep 2025 → Oct 2027 expected melanoma Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT06157827 Dec 2023 → Dec 2026 expected neuroendocrine carcinoma Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT05170958 Jan 2022 → Dec 2026 expected neoplasm Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT07331155 Feb 2026 → Dec 2028 expected — Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 2 NCT07111546 Oct 2025 → Dec 2027 expected — Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 2 NCT06783647 Jun 2025 → Dec 2026 expected high grade malignant neoplasm Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07720193 Aug 2026 → Dec 2030 expected neuroendocrine carcinoma Nanjing Leads Biolabs Co.,Ltd Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-08-28 AbClon Regulatory 차세대 이중항체 ‘AM105’ 핵심기술 일본 특허 획득… 4-1BB 시장 개화 속 글로벌 지재권 확보 abclon.com ↗
중국 리즈바이오랩스(Leads Biolabs)가 개발한 PD-L1×4-1BB 이중항체 ‘LBL-024’는 지난 7월 우선심사 대상 지정에 이어, 지난 21일 신약허가신청(NDA)이 공식 접수됐다.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as LBL-024 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783647 ↗
9

NCT07331155 ↗

NCT06157827 ↗

NCT07099430 ↗

NCT05170958 ↗

NCT07720193 ↗

NCT07281976 ↗

NCT07111546 ↗

NCT07042802 ↗

NCT07791758 ↗
Route Intravenous “LBL-024 Intravenous infusion.” NCT07042802 ↗